Drug Details

General Information of the Drug (ID: DR1960)
Name
3'-azido-3'-deoxythymidine
Synonyms
NSC602670; Azidothymidine (AZT); BW-A 509U; Aztec; 3'-Deoxy-3'-azidothymidine; Azitidin; Timazid; Zidovudine, AZT; NSC 602670; NSC-602670; Thymidine, 8CI,; Trizivir (Salt/Mix); ACMC-209hgl; 3-Azido-3-deoxythymidine; 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; CHEMBL178240; SCHEMBL13609910; 3'-epi-Azido-3'-deoxythymidine; component of Combivir (Salt/Mix); HMS3369K15; HMS3656A20; BCP03622; STL451000; STL454167; ZINC04164448; AKOS015949577; AKOS037482514; CCG-229922; MCULE-3669241621; NCGC00015044-03; NCGC00015044-04; NCGC00015044-05; NCGC00094963-01; NCGC00094963-02; NCI60_004566; FT-0601543; 1-(3-azido-2,3-dideoxypentofuranosyl)-2-hydroxy-5-methylpyrimidin-4(1H)-one; 1-(3-azido-2,3-dideoxypentofuranosyl)-4-hydroxy-5-methylpyrimidin-2(1H)-one; ZVD
    Click to Show/Hide
Molecular Type
Small molecule
Disease Human immunodeficiency virus disease [ICD-11: 1C62] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C10H13N5O4
PubChem CID
5726
Canonical SMILES
CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]
InChI
1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)
InChIKey
HBOMLICNUCNMMY-UHFFFAOYSA-N
CAS Number
CAS 30516-87-1
DrugBank ID
DB03666
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Paclitaxel      Taxus brevifolia     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model FaDu CVCL_1218 Squamous cell carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Paclitaxel combinated with low and nontoxic AZT dose was a novel cancer therapeutic approach to human pharynx faDu cells.
Target and Pathway
Target(s) Histone deacetylase (HDAC)  Molecule Info  [3]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
Reference 2 Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res. 2003 Jul;20(7):957-61.
Reference 3 Novel SAHA?bendamustine hybrid NL?101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Oncol Rep. 2020 Jul;44(1):273-282.
 Download Picture         KEGG Link